For example, and consistent with our observations that CCL5 expression in the tumor enhanced anti-PD-L1 therapy, higher CCL5 expression in the tumor has been associated with significantly improved progression-free survival in patients treated with the anti-PD-L1 immunotherapy atezolizumab in multiple clinical trials [35]. Here, CD274 is linked to neoplasm.